Literature DB >> 28771100

Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.

Onyemaechi N Okolo1, Ariel C Johnson2, Seongseok Yun3, Stacy J Arnold4, Faiz Anwer1,5.   

Abstract

Waldenström macroglobulinemia (WM) is a lymphoproliferative lymphoma that is characterized by monoclonal immunoglobulin M (IgM) protein and bone marrow infiltration. Its incidence is rare and rarer still is its ability to transform to a B-cell lymphoma, particularly the aggressive diffuse large B-cell lymphoma, which bodes a poor prognosis. When transformation includes mutations of MYC, BCL-2 and/or BCL-6, it is known as a 'double hit' or 'triple hit' lymphoma respectively. This paper presents a rare case of WM with mutations positive for MYC and BCL2, making it a case of double hit B-cell lymphoplasmacytic lymphoma with plasmatic differentiation without morphological transformation to aggressive histology like DLBCL. The paper also broadens to include discussions on current topics in the classification, diagnosis, possible causes of transformation, and treatment of WM, including transformation to double hit lymphoma. The significance of this case lies in that the presence of double hit lymphoma-like genetic mutations in WM have not been previously described in the literature and potentially such changes are harbinger of extra-nodal presentation, aggressive growth, and possibly poor prognosis, if data from other double-hit lymphoma are extrapolated.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28771100      PMCID: PMC5992568          DOI: 10.2217/imt-2017-0027

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  18 in total

Review 1.  Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Roger G Owen; Steven P Treon; Ayad Al-Katib; Rafael Fonseca; Philip R Greipp; Mary L McMaster; Enrica Morra; Gerassimos A Pangalis; Jesus F San Miguel; Andrew R Branagan; Meletios A Dimopoulos
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

Review 2.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Robert A Kyle; Steven P Treon; Raymond Alexanian; Bart Barlogie; Magnus Björkholm; Madhav Dhodapkar; T Andrew Lister; Giampaolo Merlini; Pierre Morel; Marvin Stone; Andrew R Branagan; Véronique Leblond
Journal:  Semin Oncol       Date:  2003-04       Impact factor: 4.929

3.  Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia.

Authors:  Jorge J Castillo; Joshua Gustine; Kirsten Meid; Toni Dubeau; Zachary R Hunter; Steven P Treon
Journal:  Am J Hematol       Date:  2016-07-27       Impact factor: 10.047

Review 4.  Waldenström Macroglobulinemia: Review of Pathogenesis and Management.

Authors:  Seongseok Yun; Ariel C Johnson; Onyemaechi N Okolo; Stacy J Arnold; Ali McBride; Ling Zhang; Rachid C Baz; Faiz Anwer
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-03-07

Review 5.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 6.  Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

Authors:  Stephen M Ansell; Robert A Kyle; Craig B Reeder; Rafael Fonseca; Joseph R Mikhael; William G Morice; P Leif Bergsagel; Francis K Buadi; Joseph P Colgan; David Dingli; Angela Dispenzieri; Philip R Greipp; Thomas M Habermann; Suzanne R Hayman; David J Inwards; Patrick B Johnston; Shaji K Kumar; Martha Q Lacy; John A Lust; Svetomir N Markovic; Ivana N M Micallef; Grzegorz S Nowakowski; Luis F Porrata; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Carrie A Thompson; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; Morie A Gertz
Journal:  Mayo Clin Proc       Date:  2010-08-11       Impact factor: 7.616

7.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

Authors:  Sharon Barrans; Simon Crouch; Alex Smith; Kathryn Turner; Roger Owen; Russell Patmore; Eve Roman; Andrew Jack
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 8.  Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.

Authors:  Prashant Kapoor; Jonas Paludo; Stephen M Ansell
Journal:  Curr Treat Options Oncol       Date:  2016-03

Review 9.  Current challenges and novel treatment strategies in double hit lymphomas.

Authors:  Mary Ann Anderson; Alpha Tsui; Meaghan Wall; David C S Huang; Andrew W Roberts
Journal:  Ther Adv Hematol       Date:  2016-02

10.  Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.

Authors:  Masayuki Shiseki; Akihiro Masuda; Norimichi Watanabe; Masami Fujii; Tomofumi Kimura; Kentaro Yoshinaga; Naoki Mori; Masanao Teramura; Toshiko Motoji
Journal:  Hematol Rep       Date:  2011-08-30
View more
  1 in total

1.  Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report.

Authors:  Wen-Ye Huang; Zhi-Yun Weng
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.